Stockwatch: An Ultimate Answer To A Drug Pricing Question
This article was originally published in Scrip
Executive Summary
Last week was one of those weeks that makes you grateful that the stock markets close for the weekend. While the preparations and arrival of Pope Francis brought much of New York's Fifth Avenue and its surrounds to a standstill as Thursday wore on, it was a shame that his presence in the city could not have had the same effect on the stock markets based there.
You may also be interested in...
Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
Stock Watch: Big Pharma Earnings Season Gets Messy
A post-pandemic rebound in oncology sales contrasts with the lagging revenues of drugs administered by primary care and office-based specialists. Declining COVID-19 vaccine, diagnostic and treatment revenues could add further volatility.
Stock Watch: The Pandemic Cannot Mask Roche’s Weaknesses
Declining COVID-19-related diagnostic and therapeutic sales are likely to expose long-standing weaknesses and amplify the effects of new pressures that were masked during the pandemic.